LifeMD, Inc. (NASDAQ:LFMD) Receives $11.57 Average Price Target from Brokerages

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $11.57.

A number of analysts have issued reports on the company. Mizuho began coverage on LifeMD in a research note on Wednesday, December 4th. They issued a "neutral" rating and a $7.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of LifeMD in a research report on Monday, November 11th. Lake Street Capital assumed coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a "buy" rating and a $12.00 price target for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $15.00 price target on shares of LifeMD in a research note on Friday, September 20th.

Insider Activity at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of the business's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $6.52, for a total transaction of $163,000.00. Following the transaction, the chief executive officer now owns 2,728,715 shares in the company, valued at $17,791,221.80. The trade was a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.97% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LifeMD

Several hedge funds have recently modified their holdings of LFMD. Quest Partners LLC acquired a new position in LifeMD in the 2nd quarter worth $31,000. nVerses Capital LLC acquired a new position in shares of LifeMD in the third quarter worth about $46,000. Intech Investment Management LLC purchased a new position in LifeMD in the third quarter valued at about $54,000. CWM LLC acquired a new stake in LifeMD during the 3rd quarter valued at approximately $59,000. Finally, SG Americas Securities LLC purchased a new stake in LifeMD during the 3rd quarter worth approximately $70,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

LifeMD Trading Up 2.9 %

Shares of LFMD stock traded up $0.14 during mid-day trading on Friday, hitting $5.04. 1,333,244 shares of the company's stock were exchanged, compared to its average volume of 742,021. The stock has a market cap of $218.29 million, a price-to-earnings ratio of -7.88 and a beta of 1.38. The stock has a 50-day simple moving average of $5.38 and a two-hundred day simple moving average of $5.79. LifeMD has a fifty-two week low of $3.99 and a fifty-two week high of $12.88. The company has a quick ratio of 0.78, a current ratio of 0.83 and a debt-to-equity ratio of 10.83.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.